AP3467A - Methods for designing and preparing vaccines comprising directed sequence polymer compositions via the directed expansion of epitopes - Google Patents

Methods for designing and preparing vaccines comprising directed sequence polymer compositions via the directed expansion of epitopes

Info

Publication number
AP3467A
AP3467A AP2010005261A AP2010005261A AP3467A AP 3467 A AP3467 A AP 3467A AP 2010005261 A AP2010005261 A AP 2010005261A AP 2010005261 A AP2010005261 A AP 2010005261A AP 3467 A AP3467 A AP 3467A
Authority
AP
ARIPO
Prior art keywords
directed
epitopes
designing
methods
polymer compositions
Prior art date
Application number
AP2010005261A
Other languages
English (en)
Other versions
AP2010005261A0 (en
Inventor
Eric Zanelli
Dustan Bonnin
Thomas Mathers
Original Assignee
Peptimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Peptimmune Inc filed Critical Peptimmune Inc
Publication of AP2010005261A0 publication Critical patent/AP2010005261A0/en
Application granted granted Critical
Publication of AP3467A publication Critical patent/AP3467A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AP2010005261A 2007-10-16 2008-10-16 Methods for designing and preparing vaccines comprising directed sequence polymer compositions via the directed expansion of epitopes AP3467A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US99928407P 2007-10-16 2007-10-16
US12468908P 2008-04-17 2008-04-17
PCT/US2008/011871 WO2009051797A1 (en) 2007-10-16 2008-10-16 Methods for designing and preparing vaccines comprising directed sequence polymer compositions via the directed expansion of epitopes

Publications (2)

Publication Number Publication Date
AP2010005261A0 AP2010005261A0 (en) 2010-06-30
AP3467A true AP3467A (en) 2015-11-30

Family

ID=40383826

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2010005261A AP3467A (en) 2007-10-16 2008-10-16 Methods for designing and preparing vaccines comprising directed sequence polymer compositions via the directed expansion of epitopes

Country Status (11)

Country Link
US (1) US9533037B2 (xx)
EP (2) EP2586460A1 (xx)
KR (2) KR20170075026A (xx)
AP (1) AP3467A (xx)
AU (1) AU2008311897B2 (xx)
BR (1) BRPI0817682A2 (xx)
CA (1) CA2709679A1 (xx)
IL (1) IL205171A (xx)
NZ (1) NZ585367A (xx)
WO (1) WO2009051797A1 (xx)
ZA (1) ZA201003480B (xx)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2759118A1 (en) 2008-04-17 2009-10-22 Declion Pharmaceuticals, Inc. Design and synthesis of directed sequence polymer compositions and antibodies thereof for the treatment of protein conformational disorders
EP2189919A1 (en) * 2008-11-25 2010-05-26 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Method and system for building a phylogeny from genetic sequences and using the same for recommendation of vaccine strain candidates for the influenza virus
EP2852608A4 (en) * 2012-05-21 2016-05-04 Distributed Bio Inc EPITOPIC CROPPING BY VARIABLE EFFECTIVE ANTIGEN SURFACE CONCENTRATION
ES2441880B1 (es) * 2012-07-06 2014-11-13 Universidad De Granada Composición basada en polipéptidos para el tratamiento de miasis
WO2014100816A2 (en) * 2012-12-21 2014-06-26 University Of Miami Ghrh agonists for islet cell transplantation and function and the treatment of diabetes
US20230285543A1 (en) * 2020-07-15 2023-09-14 University Of Southern California Peptide epitope vaccines for covid-19 and method of designing, making and using the same
WO2022235678A1 (en) * 2021-05-03 2022-11-10 Ohio State Innovation Foundation Human anti-coronavirus peptide vaccines and methods of their use

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006128294A1 (en) * 2005-06-01 2006-12-07 Variation Biotechnologies Inc. Peptide-based influenza vaccine formulation

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2677363A1 (fr) 1991-06-07 1992-12-11 Pasteur Institut Compositions a base de peptides multiepitopiques, leur procede d'obtention et leurs applications, notamment en tant que vaccins.
ATE415173T1 (de) * 1993-09-14 2008-12-15 Pharmexa Inc Pan dr-bindeproteinen zur erhöhung der immunantwort
US5770565A (en) 1994-04-13 1998-06-23 La Jolla Cancer Research Center Peptides for reducing or inhibiting bone resorption
US5800808A (en) 1994-05-24 1998-09-01 Veda Research And Development Co., Ltd. Copolymer-1 improvements in compositions of copolymers
US5858964A (en) 1995-04-14 1999-01-12 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising synthetic peptide copolymer for prevention of GVHD
US6093396A (en) * 1996-09-27 2000-07-25 Diamyd Therapeutics Ab Modified glutamic acid decarboxylase (GAD)
US20030223995A1 (en) * 1996-12-23 2003-12-04 Advanced Biotherapy, Inc. Treatment of pemphigus vulgaris
FR2765688B1 (fr) * 1997-07-04 1999-09-10 Pasteur Institut Reactif de detection et de suivi des infections provoquees par le virus d'epstein-barr et ses applications
US6541011B2 (en) * 1998-02-11 2003-04-01 Maxygen, Inc. Antigen library immunization
WO1999045954A1 (en) 1998-03-13 1999-09-16 Epimmune, Inc. Hla-binding peptides and their uses
JPH11330431A (ja) 1998-05-18 1999-11-30 Nec Corp 不揮発性半導体記憶装置の製造方法
EP1098902A4 (en) 1998-07-23 2002-07-24 Yeda Res & Dev TREATMENT OF AUTOIMMUNE DISEASES BY COPOLYMER 1 AND SIMILAR COPOLYMERS AND PEPTIDES
EP1105414A2 (en) 1998-07-23 2001-06-13 President And Fellows of Harvard College Synthetic peptides and methods of use for autoimmune disease therapies
US6514938B1 (en) 1998-09-25 2003-02-04 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
US7118874B2 (en) * 1998-10-09 2006-10-10 Variation Biotechnologies Inc. Immunogenic formulation and process for preparation thereof
AU775073C (en) 1998-11-12 2007-05-03 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising synthetic peptide copolymers and methods for preventing and treating GVHD and HVGD
US6376246B1 (en) 1999-02-05 2002-04-23 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination
US6917882B2 (en) 1999-01-19 2005-07-12 Maxygen, Inc. Methods for making character strings, polynucleotides and polypeptides having desired characteristics
EP1151409A1 (en) 1999-01-18 2001-11-07 Maxygen, Inc. Methods of populating data stuctures for use in evolutionary simulations
US6368861B1 (en) 1999-01-19 2002-04-09 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination
US6961664B2 (en) 1999-01-19 2005-11-01 Maxygen Methods of populating data structures for use in evolutionary simulations
ES2341217T3 (es) 1999-01-19 2010-06-17 Maxygen, Inc. Recombinacion de acidos nucleicos mediada por oligonucleotidos.
US7024312B1 (en) 1999-01-19 2006-04-04 Maxygen, Inc. Methods for making character strings, polynucleotides and polypeptides having desired characteristics
US6268488B1 (en) 1999-05-25 2001-07-31 Barbas, Iii Carlos F. Prodrug activation using catalytic antibodies
US6844314B2 (en) 2000-01-20 2005-01-18 Yeda Research Development Co., Ltd. Use of copolymer 1 and related peptides and polypeptides and T cells treated therewith for neuroprotective therapy
NZ520282A (en) 2000-06-07 2004-09-24 Yeda Res & Dev The use of copolymer 1 and related peptides and polypeptides and T cells treated therewith for neuroprotective therapy
US20040003888A1 (en) 2000-07-11 2004-01-08 Laurence Mott Process for the manufacture of an improved floor element
IL157073A0 (en) 2001-01-24 2004-02-08 Harvard College Therapeutic peptides for demyelinating conditions
CA2440443A1 (en) 2001-03-12 2002-09-19 Robert O. Fox Computer-based strategy for peptide and protein conformational ensemble enumeration and ligand affinity analysis
NZ532199A (en) 2001-10-03 2008-02-29 Harvard College Copolymers for suppression of autoimmune diseases, and methods of use
CN100560131C (zh) 2001-10-22 2009-11-18 斯克里普斯研究学院 抗体靶向化合物
US20060018915A1 (en) 2002-04-05 2006-01-26 Glenn Ishioka Heteroclitic analogs and related methods
CA2540890A1 (en) 2003-10-03 2005-04-14 Bayhill Therapeutics, Inc. Treatment of demyelinating autoimmune disease with modified ordered peptides
JP2008500276A (ja) 2004-02-02 2008-01-10 ミクスチャー サイエンセズ、 インク． 免疫調節活性を有するペプチド混合物
JP2007527873A (ja) 2004-03-01 2007-10-04 ペプチミューン，インコーポレイテッド 自己免疫疾患の治療のための方法および組成物
US7084247B2 (en) * 2004-03-11 2006-08-01 Peptimmune, Inc. Identification of self and non-self antigens implicated in autoimmune diseases
WO2005103679A2 (en) 2004-04-21 2005-11-03 Algonomics Nv Method for affinity scoring of peptide/protein complexes
JP5495490B2 (ja) 2004-05-07 2014-05-21 アレス トレーディング エスエイ ランダム共重合体を用いる疾患の治療方法
US20060194725A1 (en) * 2004-05-07 2006-08-31 James Rasmussen Methods of treating disease with random copolymers
WO2006031727A2 (en) 2004-09-13 2006-03-23 President And Fellows Of Harvard College Peptides for treatment of autoimmune diseases
CA2585462A1 (en) * 2004-10-29 2006-05-11 Benaroya Research Institute At Virginia Mason Methods of generating antigen-specific cd4+cd25+ regulatory t cells, compositions and methods of use
WO2006056027A1 (en) * 2004-11-29 2006-06-01 The Council Of The Queensland Institute Of Medical Research Human cytomegalovirus immunotherapy
EP1676859A1 (en) 2004-12-30 2006-07-05 Pevion Biotech Ltd. Immunogenic compositions of cyclic peptides derived from the beta-amyloid peptide
EP1820511A1 (en) 2006-02-20 2007-08-22 Prolmmune Limited MHC binding peptides and their uses
US8378072B2 (en) * 2006-04-13 2013-02-19 Declion Pharmaceuticals, Inc. Methods for designing and synthesizing directed sequence polymer compositions via the directed expansion of epitope permeability
US20090036653A1 (en) * 2006-04-13 2009-02-05 Peptimmune, Inc. Methods for the directed expansion of epitopes for use as antibody ligands
US20100150941A1 (en) 2006-09-13 2010-06-17 Dso National Laboratories Hemagglutinin antibody and uses thereof
FI20060946A0 (fi) 2006-10-26 2006-10-26 Glykos Finland Oy Influenssaviruksen nukleiinihappoja ja peptidejä
US20090162383A1 (en) * 2006-12-26 2009-06-25 Padlan Eduardo A Method for designing vaccines against constantly mutating pathogens
AU2008287530A1 (en) * 2007-05-07 2009-02-19 Peptimmune, Inc. Methods for the directed expansion of epitopes for use as antibody ligands
EP2238146A4 (en) 2008-01-03 2012-03-21 Massachusetts Inst Technology HEMAGGLUTININ POLYPEPTIDES, REAGENTS, AND METHODS RELATING THERETO
AT506535B1 (de) 2008-02-22 2010-04-15 Affiris Forschungs & Entwicklungs Gmbh Vaccine enthaltend alpha-synuclein-mimotope auf basis von peptiden
CA2759118A1 (en) * 2008-04-17 2009-10-22 Declion Pharmaceuticals, Inc. Design and synthesis of directed sequence polymer compositions and antibodies thereof for the treatment of protein conformational disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006128294A1 (en) * 2005-06-01 2006-12-07 Variation Biotechnologies Inc. Peptide-based influenza vaccine formulation

Also Published As

Publication number Publication date
CA2709679A1 (en) 2009-04-23
AU2008311897B2 (en) 2015-03-26
KR101751406B1 (ko) 2017-06-27
EP2207566A1 (en) 2010-07-21
AU2008311897A1 (en) 2009-04-23
US9533037B2 (en) 2017-01-03
US20110129497A1 (en) 2011-06-02
WO2009051797A1 (en) 2009-04-23
IL205171A (en) 2016-10-31
IL205171A0 (en) 2010-11-30
AP2010005261A0 (en) 2010-06-30
BRPI0817682A2 (pt) 2015-04-07
KR20170075026A (ko) 2017-06-30
EP2586460A1 (en) 2013-05-01
KR20100096092A (ko) 2010-09-01
ZA201003480B (en) 2012-10-31
NZ585367A (en) 2012-12-21

Similar Documents

Publication Publication Date Title
HK1246650A1 (zh) 抗病毒免疫的方法和組合物
HK1223382A1 (zh) 免疫療法的新型免疫抗原表位
AP2010005173A0 (en) Compositions comprising pneumococcal antigens
ZA201203709B (en) Immunogenic compositions and methods
IL193397A0 (en) Hpv antigens, vaccine compositions, and related methods
EP2087128A4 (en) COMPOSITIONS AND METHODS FOR IMMUNOMINANT ANTIGENES
EP2219458A4 (en) COMPOSITIONS AND METHOD FOR THE PRODUCTION OF ANTIBODIES
ZA201003480B (en) Methods for designing and preparing vaccines comprising directed sequence polymer compositions via the directed expansion of epitopes
ZA201006944B (en) Compositions and methods for preparing and using same
EP2089051A4 (en) INCREASED IMMUNOGENICITY OF TUMOR ASSOCIATED ANTIGENES BY ADDITION OF ALPHA GAL EPITOPES
EP2260010A4 (en) ADJUVANT FOR CONCRETE AND CEMENT FORMULATIONS AND PROCESSES FOR PREPARING THE SAME
EP2152301A4 (en) TRYPANOSOME ANTIGENS, VACCINE COMPOSITIONS AND RELATED METHODS
ZA200906693B (en) Rapid deep-section cure silicone compositions
EP2205276A4 (en) ANTI-IL-12 / 23P40 ANTIBODIES, EPITOPES, FORMULATIONS, COMPOSITIONS, METHODS AND USES
EP2376089A4 (en) CANCER VACCINE COMPOSITIONS AND THEIR METHODS OF USE
EP2178558A4 (en) ANTIGENS YERSINIA PESTIS, VACCINE COMPOSITIONS, AND ASSOCIATED METHODS
EP2515940A4 (en) IMMUNOGENIC COMPOSITIONS AND CORRESPONDING METHODS
EP2134361A4 (en) COMPOSITIONS AND METHODS FOR INCREASING THE IMMUNOGENICITY OF GLYCOPROTEIN VACCINES
ZA201004337B (en) Bluetongue virus vaccine and immunogenic compositions, methods of use and methods of producing the same
IL214211A0 (en) Stable vaccine compositions and methods for preparing the same
EP2076544A4 (en) ANTI-OBESITY IMMONOGENIC HYBRID POLYPEPTIDES AND ANTI-OBESITY VACCINE COMPOSITION COMPRISING THE SAME
EP2496593A4 (en) AMPHIPHILIC COMPOSITIONS AND PREPARATION METHODS USING THE SAME